Health care startups that raised Series D or later in Europe
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| bit.bio | Cambridge | Series D | $25.0M | 2026-11-04 |
| Leo Cancer Care | Harley | Series D | $65.0M | 2026-07-08 |
| CellCentric | Cambridge | Series D | $220.0M | 2026-05-06 |
| MedTrace Pharma | Lyngby | Series F | $11.1M | 2025-05-12 |
| Alentis Therapeutics | Allschwil | Series D | $181.4M | 2024-11-12 |
| CatalYm | Planegg | Series D | $150.0M | 2024-07-16 |
| Huma | London | Series D | $80.0M | 2024-07-16 |
| SkyCell | Zürich | Series D | $59.0M | 2024-06-25 |
8 rows of the CSV in 5 of its 18 columns.
- The 75 health care startups in Europe whose last round is Series D or later have raised $8.4B in total.
- 11 of them closed their most recent round in the last 12 months, $1.5B combined.
- The largest of those rounds is Alan's $544.6M Series G, dated June 2026.
- The most recent is bit.bio's $25.0M Series D on 4 November 2026.
- Bayern Kapital is an investor in 5 of them, more than any other fund.
- Biotech is the most common other sector, with 41 companies (55%).
- 0% were founded in 2020 or later; the median founding year is 2008.
- The most common team size is 11 to 50 employees (53% of companies with a recorded size).
- 3 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
15 of 75| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| bit.bio | Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. | Biotech | Cambridge, United Kingdom | Series D | $25.0M | 2026-11-04 | $250.0M | Metaplanet, Foresite Capital | 101 to 250 | 2016 |
| Leo Cancer Care | Leo Cancer Care develops radiation therapy technologies that treat cancer in upright patient positions. | Health care | Harley, United Kingdom | Series D | $65.0M | 2026-07-08 | $130.3M | Alumni Ventures, EDBI, Serra Ventures +1 | 11 to 50 | 2016 |
| CellCentric | CellCentric develops small molecule therapies for treating cancer and multiple myeloma. | Biotech | Cambridge, United Kingdom | Series D | $220.0M | 2026-05-06 | $475.7M | Innovate UK, 5Y Capital, RA Capital Management +2 | 11 to 50 | 2003 |
| MedTrace Pharma | MedTrace Pharma helps doctors diagnose critically ill patients faster and more accurately. | Biotech | Lyngby, Denmark | Series F | $11.1M | 2025-05-12 | $63.4M | European Innovation Council, Vaekstfonden, ATP +1 | 11 to 50 | 2015 |
| Alentis Therapeutics | Alentis Therapeutics develops novel therapeutics for advanced liver disease and cancer. | Biotech | Allschwil, Switzerland | Series D | $181.4M | 2024-11-12 | Bpifrance, HTGF (High-Tech Gruenderfonds), RA Capital Management +2 | 51 to 100 | 2019 | |
| CatalYm | CatalYm develops immunotherapies to treat cancer. | Biotech | Planegg, Germany | Series D | $150.0M | 2024-07-16 | $260.9M | Bayern Kapital, Forbion Capital Partners, Novartis Venture Fund +1 | 11 to 50 | 2016 |
| Huma Unicorn | Huma offers a health platform for remote patient monitoring and biological data collection in preventive care. | Artificial intelligence | London, United Kingdom | Series D | $80.0M | 2024-07-16 | $322.6M | Samsung NEXT, Unilever Ventures, Leaps by Bayer +1 | 501 to 1,000 | 2011 |
| SkyCell | SkyCell develops temperature-controlled logistics containers for the pharmaceutical industry. | Health care | Zürich, Switzerland | Series D | $59.0M | 2024-06-25 | M&G Investments, MVM Life Science Partners, Tybourne Capital Management +1 | 101 to 250 | 2013 | |
| Phagenesis | Phagenesis develops a device that treats dysphagia, a condition that makes swallowing food unsafe. | Biotech | Manchester, United Kingdom | Series D | $42.0M | 2024-03-04 | $71.4M | MedTech Innovator, EQT Life Sciences, Northern Gritstone +2 | 11 to 50 | 2007 |
| Lunaphore | Lunaphore is a life sciences company that creates technologies enabling spatial biology in all laboratories. | Biotech | Lausanne, Switzerland | Series D | $32.7M | 2023-03-23 | Venture Kick, VentureOut, redalpine | 11 to 50 | 2014 | |
| iThera Medical | iThera Medical develops proprietary MSOT imaging technology for preclinical and clinical applications. | Biotech | Munich, Germany | Series D | $13.8M | 2022-12-21 | $42.3M | European Innovation Council, Bayern Kapital, German Federal Ministry of Research, Technology and Space +1 | 11 to 50 | 2010 |
| Kry Unicorn | Kry helps patients make active choices about their health alongside healthcare professionals. | Health care | Stockholm, Sweden | Series D | $160.0M | 2022-07-21 | $729.4M | Accel, Index Ventures, Creandum +2 | 1,001 to 5,000 | 2015 |
| Swile Unicorn | Swile provides employee benefits through an all-in-one smartcard and an app. | Commerce | Paris, France | Series D | $199.9M | 2021-10-11 | Bpifrance, Index Ventures, SoftBank +2 | 501 to 1,000 | 2018 | |
| Biosystems International | Biosystems International develops blood-based diagnostics for cancer and chronic diseases. | Biotech | Debrecen, Hungary | Series D | $2.8M | 2020-10-29 | Societe Generale Asset Management, Amundi Private Equity Funds | 11 to 50 | 2004 | |
| Phenex Pharmaceuticals | Phenex Pharmaceuticals discovers and develops novel pharmaceutical drugs. | Biotech | Heidelberg, Germany | Series D | $6.5M | 2012-10-31 | KfW, Creathor Ventures, LBBW VC +2 | 11 to 50 | 2002 |
Table 1. Health care startups that raised Series D or later in Europe: the 15 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 75.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CellCentric | CellCentric develops small molecule therapies for treating cancer and multiple myeloma. | Biotech | Cambridge, United Kingdom | Series D | $220.0M | 2026-05-06 | $475.7M | Innovate UK, 5Y Capital, RA Capital Management +2 | 11 to 50 | 2003 |
| 2 | Leo Cancer Care | Leo Cancer Care develops radiation therapy technologies that treat cancer in upright patient positions. | Health care | Harley, United Kingdom | Series D | $65.0M | 2026-07-08 | $130.3M | Alumni Ventures, EDBI, Serra Ventures +1 | 11 to 50 | 2016 |
| 3 | bit.bio | Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. | Biotech | Cambridge, United Kingdom | Series D | $25.0M | 2026-11-04 | $250.0M | Metaplanet, Foresite Capital | 101 to 250 | 2016 |
Table 2. Health care startups that raised Series D or later in Europe: the 3 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Bayern Kapital | Venture capital firm | Landshut, Germany | 5 | 7% | ||
| 2 | KfW | Government investment office | Frankfurt, Germany | 3 | 4% | ||
| 3 | RA Capital Management | Startup incubator | Boston, United States | 2 | 3% | 1 | CellCentric |
| 4 | European Innovation Council | Startup accelerator | Brussels, Belgium | 2 | 3% | ||
| 5 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 2 | 3% | ||
| 6 | Bpifrance | Government investment office | Maisons-alfort, France | 2 | 3% | ||
| 7 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 2 | 3% | ||
| 8 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 2 | 3% | ||
| 9 | MVM Life Science Partners | Venture capital firm | London, United Kingdom | 2 | 3% | ||
| 10 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 2 | 3% | ||
| 11 | Venture Kick | Startup incubator | Schlieren, Switzerland | 2 | 3% | ||
| 12 | Index Ventures | Venture capital firm | San Francisco, United States | 2 | 3% | ||
| 13 | MIG Capital | Venture capital firm | Munich, Germany | 2 | 3% | ||
| 14 | Foresite Capital | Private equity firm | San Francisco, United States | 1 | 1% | 1 | bit.bio |
| 15 | Metaplanet | Venture capital firm | Tallinn, Estonia | 1 | 1% | 1 | bit.bio |
Table 3. Health care startups that raised Series D or later in Europe: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
Table 4. Health care startups that raised Series D or later in Europe by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series D+ | 75 | 100% | $32.7M |
Table 5. Health care startups that raised Series D or later in Europe by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United Kingdom | 21 | 28% |
| Switzerland | 12 | 16% |
| France | 11 | 15% |
| Germany | 11 | 15% |
| Belgium | 5 | 7% |
| The Netherlands | 3 | 4% |
| Sweden | 2 | 3% |
| Poland | 2 | 3% |
| Austria | 1 | 1% |
| Denmark | 1 | 1% |
| Ireland | 1 | 1% |
| Malta | 1 | 1% |
Table 6. Health care startups that raised Series D or later in Europe by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Paris | 7 | 9% |
| Cambridge | 6 | 8% |
| Munich | 5 | 7% |
| London | 4 | 5% |
| Manchester | 3 | 4% |
| Zürich | 2 | 3% |
| Stockholm | 2 | 3% |
| Basel | 1 | 1% |
| Bristol | 1 | 1% |
| Harley | 1 | 1% |
| Horw | 1 | 1% |
| Utrecht | 1 | 1% |
Table 7. Health care startups that raised Series D or later in Europe by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 9% | $25.0M |
| October 2026 | 1 | 9% | $134.7M |
| August 2026 | 1 | 9% | $25.0M |
| July 2026 | 1 | 9% | $65.0M |
| June 2026 | 3 | 27% | $678.6M |
| May 2026 | 1 | 9% | $220.0M |
| January 2026 | 2 | 18% | $246.7M |
| November 2025 | 1 | 9% | $115.0M |
Table 8. Health care startups that raised Series D or later in Europe: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 10 | 13% | $1.4B |
| 2025 | 4 | 5% | $201.1M |
| 2024 | 11 | 15% | $992.6M |
| 2023 | 2 | 3% | $64.9M |
| 2022 | 6 | 8% | $290.2M |
| 2021 | 5 | 7% | $458.5M |
Table 9. Health care startups that raised Series D or later in Europe by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2015 to 2019 | 15 | 20% |
| 2010 to 2014 | 17 | 23% |
| Before 2010 | 43 | 57% |
Table 10. Health care startups that raised Series D or later in Europe by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 2 | 3% |
| 11 to 50 | 38 | 53% |
| 51 to 100 | 8 | 11% |
| 101 to 250 | 14 | 19% |
| 251 to 500 | 2 | 3% |
| 501 to 1,000 | 5 | 7% |
| 1,001 to 5,000 | 2 | 3% |
| 10,001 or more | 1 | 1% |
Table 11. Health care startups that raised Series D or later in Europe by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its most recent funding round is Series D or later and its headquarters is in Europe. On 16 November 2026 that is 75 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 15 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 75 rows: 8 have no round amount, 0 no city and 22 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in Europe whose last round is Series D or later are on the list?
- 75, in the file dated 16 November 2026. 11 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 75 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.